### 38. welcomes the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening tests and the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing); emphasises that those programmes should be regularly evaluated by the competent national authorities; calls for research efforts to be fostered in order to assess , in close cooperation with the iarc and the who , the possible inclusion of new science-based cancer screening programmes (including lung , prostate , stomach and ovarian cancers) in the recommendation; ### 38. welcomes the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening tests and the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing , genomic testing); emphasises that those programmes should be regularly evaluated by the competent national authorities; calls for research efforts to be fostered in order to assess , in close cooperation with the iarc and the who , the possible inclusion of new science-based cancer screening programmes (including lung , prostate , stomach and ovarian cancers) in the recommendation;


### 40. stresses the importance of increasing the uptake of cancer screening and early detection among eu citizens through european awareness days , motivation surveys and better implementation of existing communication campaigns; ### 40. stresses the importance of increasing the uptake of cancer screening and early detection among eu citizens through european awareness days , motivation surveys and better implementation of existing communication campaigns; calls on the member states to implement awareness-raising actions with a view to improve participation in cancer screening; encourages to actively work on educational strategies in primary healthcare centres;


### 41. calls for reinforced cooperation with third countries to encourage the organisation of screening campaigns , in particular for women’s cancers and notably in low- and middle-income countries; ### 41. calls for reinforced cooperation with third countries to encourage the organisation of screening campaigns , taking into account the particularities of women's and men’s cancers in low- and middle-income countries;


### 42. deplores the fact that eu patients still face challenges in accessing healthcare services in other member states and that only a minority of patients are aware of their right to seek cross-border healthcare; emphasises the need for better implementation of , and an improved financial model for , the cross-border healthcare directive25 to allow for mobility and access to highly specialised equipment and care through the reinforcement of the national contact points (ncps) by providing them with more budgetary resources , and calls for an increase in the number of information campaigns on patients’ rights to cross-border healthcare; emphasises the need to facilitate the process , through the revision of the cross-border healthcare directive , for patients who travel abroad for clinical trials and face issues such as a lack of clarity on follow-up protocols after their return home and on coverage of costs related to their clinical trial participation by national insurance agencies; calls on the commission and the member states to work together to conduct regular evaluations of the commission’s ehealth strategy from 2018 to ensure interconnected electronic health records for cancer patients at regional , national and european level; ### 42. deplores the fact that eu patients still face challenges in accessing healthcare services in other member states and that only a minority of patients are aware of their right to seek cross-border healthcare; emphasises the need for better implementation of , and an improved financial model for , the cross-border healthcare directive25 to allow for mobility and access to highly specialised equipment and care through the reinforcement of the national contact points (ncps) by providing them with more budgetary resources , and calls for an increase in the number of information campaigns on patients’ rights to cross-border healthcare; emphasises the need to facilitate the process , through the revision of the cross-border healthcare directive , for patients who travel abroad for clinical trials and face issues such as a lack of clarity on follow-up protocols after their return home and on coverage of costs related to their clinical trial participation by national insurance agencies; calls on the commission and the member states to work together to conduct regular evaluations of the commission’s ehealth strategy from 2018 to ensure interconnected electronic health records , better interoperability , as well as improved data quality and cybersecurity for cancer patients at regional , national and european level;


### 42. deplores the fact that eu patients still face challenges in accessing healthcare services in other member states and that only a minority of patients are aware of their right to seek cross-border healthcare; emphasises the need for better implementation of , and an improved financial model for , the cross-border healthcare directive25 to allow for mobility and access to highly specialised equipment and care through the reinforcement of the national contact points (ncps) by providing them with more budgetary resources , and calls for an increase in the number of information campaigns on patients’ rights to cross-border healthcare; emphasises the need to facilitate the process , through the revision of the cross-border healthcare directive , for patients who travel abroad for clinical trials and face issues such as a lack of clarity on follow-up protocols after their return home and on coverage of costs related to their clinical trial participation by national insurance agencies; calls on the commission and the member states to work together to conduct regular evaluations of the commission’s ehealth strategy from 2018 to ensure interconnected electronic health records for cancer patients at regional , national and european level; ### 42. deplores the fact that eu patients still face challenges in accessing healthcare services in other member states and that only a minority of patients are aware of their right to seek cross-border healthcare; emphasises the need for better implementation of , and an improved financial model for , the cross-border healthcare directive25 to allow for mobility and access to highly specialised equipment and care through the reinforcement of the national contact points (ncps) by providing them with budgetary resources which cover the real health needs of the member state concerned , and calls for an increase in the number of information campaigns on patients’ rights to cross-border healthcare; emphasises the need to facilitate the process , through the revision of the cross-border healthcare directive , for patients who travel abroad for clinical trials and face issues such as a lack of clarity on follow-up protocols after their return home and on coverage of costs related to their clinical trial participation by national insurance agencies; calls on the commission and the member states to work together to conduct regular evaluations of the commission’s ehealth strategy from 2018 to ensure interconnected electronic health records for cancer patients at regional , national and european level;


### 44. calls for full recognition of medical oncology as a specialist discipline , the establishment of pan-european quality standards for administering and supervising medical treatments for cancer , and the facilitation of patients’ access to cancer specialists so that they may benefit from innovations and access to early clinical trials on new promising drugs; ### 44. calls for full recognition of medical oncology as a specialist discipline , the establishment of pan-european quality standards for administering and supervising medical treatments for cancer , and the facilitation of patients’ access to cancer specialists so that they may benefit from innovations and access to early clinical trials on new promising drugs , including paediatric drugs ;


### 44. calls for full recognition of medical oncology as a specialist discipline , the establishment of pan-european quality standards for administering and supervising medical treatments for cancer , and the facilitation of patients’ access to cancer specialists so that they may benefit from innovations and access to early clinical trials on new promising drugs; ### 44. calls for full recognition of medical oncology as a specialist discipline , the establishment of pan-european quality standards for administering and supervising medical treatments for cancer , and the facilitation of patients’ access to cancer specialists so that they may benefit from innovations and access to early clinical trials on new promising health technologies;


### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; ### 48. calls on the commission to promote , and on member states to review the role and responsibilities of general practitioners , paediatricians and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls on the commission to prepare guidance for the development of multidisciplinary decision-making throughout the treatment process bringing together various cancer specialists;


### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; ### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care physicians , given their importance in advising on diagnostic tests and specialist oncological examinations , as well as during cancer treatments and follow-up care , and stresses the importance of supporting patients after treatment , through multidisciplinary approaches that provide psychological support , rehabilitation and specify therapies to overcome sexual dysfunction , very common in all cancer patients; calls for the development of a multidisciplinary decision-making process in the framework of dedicated concertation meetings bringing together various oncological specialists;


### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; ### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians , nurses and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists;


### 49. considers that the eu regulatory framework for the recognition of professional qualifications should be broadened to allow for the standardisation of cancer nursing education; ### 49. considers that the scope of directive 2005/36/ec1a should be revised to allow for the mutual recognition of cancer nursing education;


### 49. considers that the eu regulatory framework for the recognition of professional qualifications should be broadened to allow for the standardisation of cancer nursing education; ### 49. considers that the eu regulatory framework for the recognition of professional qualifications should be broadened to allow for the standardisation of cancer nursing education and palliative care education;


### 50. calls on the member states to take preventive measures against the risk of burnout among cancer care professionals; ### 50. calls on the member states to incorporate and promote preventive measures against the risk of burnout among cancer care professionals within their national cancer control plans;


### 51. encourages , where possible and safe , the use of ambulatory cancer treatments in order to preserve the quality of life of patients; calls on member states to implement or improve e-health technologies and telemedicine services to ensure the continuity of cancer care; ### 51. encourages , where it is practicable and safe to do so , the use of ambulatory cancer treatments in order to preserve the quality of life of patients; calls on member states to implement or improve e-health technologies and telemedicine services to ensure the continuity of out-of-hospital cancer care;


### 51. encourages , where possible and safe , the use of ambulatory cancer treatments in order to preserve the quality of life of patients; calls on member states to implement or improve e-health technologies and telemedicine services to ensure the continuity of cancer care; ### 51. encourages , where possible and safe , the use of ambulatory cancer treatments in order to preserve the quality of life of patients and their families; calls on member states to implement or improve e-health technologies , telemedicine and telecare services to ensure the continuity of cancer care;


### 52. calls on the member states to provide optimal relief for advanced-stage cancer patients at the end of their lives in order to ease their pain and discomfort while preserving their dignity; supports more intensive exchanges and the implementation of best practices on hospice and palliative care at eu level; encourages member states to assess the number of palliative units in each region and to ensure sustainable funding and sufficient and well-trained human resources; ### 52. calls on the member states to provide integral and multidisciplinary palliative care for cancer patients at the end of their lives in order to ease their pain and discomfort , promoting comfort care and ensuring the nurse or carers presence while preserving their dignity; supports more intensive exchanges and the implementation of best practices on hospice and palliative home care at eu level; encourages member states to maximise the number of palliative units in each region and to ensure sustainable funding and sufficient and well-trained human resources;


### 52. calls on the member states to provide optimal relief for advanced-stage cancer patients at the end of their lives in order to ease their pain and discomfort while preserving their dignity; supports more intensive exchanges and the implementation of best practices on hospice and palliative care at eu level; encourages member states to assess the number of palliative units in each region and to ensure sustainable funding and sufficient and well-trained human resources; ### 52. calls on the member states to provide , within their national cancer plans , optimal relief for advanced-stage cancer patients in order to ease their pain and discomfort during end-of-life care , while preserving their dignity and maximising their autonomy; supports more intensive exchanges and the implementation of best practices on hospice and palliative care at eu level; encourages member states to assess the number of palliative units in each region and to ensure sustainable funding and sufficient and well-trained human resources;


### 53. encourages the commission and the member states to adopt specific quality assurance criteria (including adequate organisations , infrastructures and competences , multidisciplinary practice , continuing education for professionals , patient education and participation in clinical research) for accreditation standards to be applied to public and private hospitals treating cancer patients , in order to ensure the efficient , safe and equal management of cancers all over the eu; ### 53. encourages the commission and the member states to adopt specific quality assurance criteria (including adequate organisations , infrastructures and competences , multidisciplinary practice , continuing education for professionals , patient education , participation in clinical research , pain management and palliative care services) for accreditation standards to be applied to public and private hospitals treating cancer patients , as well as in primary care centres that provide home follow-up to these patients and their families , in order to ensure the efficient , safe and equal management of cancers all over the eu;


### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; ### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; recommends that a diversity of cancer specialties and medical disciplines (such as respiratory , nephrology , cardiology , gastroenterology , etc.) be involved from the start in the work of the envisioned eu network of national comprehensive cancer centres to reinforce multi-disciplinary collaboration , therefore improving outcomes for patients;


### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; ### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres;


### 55. calls for the identification , reinforcement or creation in each member state of a national cancer control programme (nccp) , consisting of a unique structure , possibly a national cancer institute , in charge of the implementation and follow-up of the respective nccps , with adequate objectives and resources; recommends that the nccps are set up in coherence with the european guide for quality national cancer control programmes initiated by the european partnership for action against cancer (epaac); welcomes the setting up of a network of these organisations coordinated by the european cancer institute; ### 55. calls for the identification , reinforcement or creation in each member state of a national cancer control programme (nccp) , consisting of designated implementation bodies responsible for the implementation and follow-up of the respective nccps , with adequate objectives and resources; recommends that the nccps are set up in coherence with the european guide for quality national cancer control programmes initiated by the european partnership for action against cancer (epaac); welcomes the establishment of a european network of these national bodies;


### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children; ### 56. calls on the commission to develop a plan of collaboration between member states in order to improve the functioning of the european medicines market so as to guarantee equal access and availability to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children;


### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children; ### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , encourage the use of generic and biosimilar medicines and improve cancer treatments for adults and children;


### 58. notes that cancer patients are frequently affected by medicine shortages; calls on the commission to present a specific strategy for managing shortages of all medicines and medical products in europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; ### 58. notes that cancer patients are frequently affected by medicine shortages; calls on the commission to present a specific strategy to improve collaboration between member states in order to manage and prevent shortages of all essential medicines and medical products in europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;


### 60. points out that generic and biosimilar medicines enable efficient and safe cancer care , increased competition and savings for healthcare systems , thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed; ### 60. points out that generic and biosimilar medicines enable efficient and safe cancer care , increased competition and savings for healthcare systems , thus helping to improve access to medicines for patients; stresses that their market entry should not be hampered or delayed provided that intellectual property rights are respected;


### 62. insists on the need to ensure equal access to affordable drugs , in particular cancer drugs , within the eu; calls for collective negotiation on the price of medicines with pharmaceutical industries , as per the beneluxa initiative on pharmaceutical policy and the valetta declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; ### 62. acknowledges the need to ensure equal access to affordable drugs , in particular cancer drugs , within the eu; points out the possibility for member states to engage in voluntary collective negotiation on the price of medicines with pharmaceutical industries , as per the beneluxa initiative on pharmaceutical policy and the valetta declaration; highlights the vastly different conditions , national healthcare and reimbursement systems , patient profiles , infrastructure capacities and financial burdens of member states as some of the main factors dictating the pricing of medicines;


### 62. insists on the need to ensure equal access to affordable drugs , in particular cancer drugs , within the eu; calls for collective negotiation on the price of medicines with pharmaceutical industries , as per the beneluxa initiative on pharmaceutical policy and the valetta declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; ### 62. insists on the need to ensure equal access to affordable drugs , in particular cancer drugs , within the eu; calls for voluntary collective negotiation on the price of medicines with pharmaceutical industries , as per the beneluxa initiative on pharmaceutical policy and the valetta declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;


### 62. insists on the need to ensure equal access to affordable drugs , in particular cancer drugs , within the eu; calls for collective negotiation on the price of medicines with pharmaceutical industries , as per the beneluxa initiative on pharmaceutical policy and the valetta declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research; ### 62. insists on the need to ensure equal access to safe , effective and affordable drugs , in particular cancer drugs , within the eu; calls for collective negotiation on the price of medicines with pharmaceutical industries , as per the beneluxa initiative on pharmaceutical policy and the valletta declaration; considers that pharmaceutical companies should respect conditionalities on charging an affordable price for medicines developed in the framework of publicly funded research;


### 63. strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at eu level; ### 63. calls for assessing the possibility for the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at eu level; calls on the commission to make an assessment of the icu joint procurement initiative and take the lesson learned to improve this tool; considers that this should not impact pre-existing contractual agreements with suppliers of medical countermeasures and should be carried out in accordance with directive 2014/24/eu on public procurement1a in a transparent manner , while respecting the following conditions: the procurement process , criteria , timelines , specifications , and formalities must be transparent and workable; a preliminary consultation phase involving potential participating manufacturers must take place; clear volume commitments irrespective of the selected supply modality must be ensured;


### 63. strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at eu level; ### 63. acknowledges the possibility for the extension of joint procurement procedures on the basis of a joint assessment of the value of the product , for cancer medicines to improve affordability and access to cancer treatments at eu level; insists that a thorough impact assessment taking stock of the current and ongoing experience of eu joint procurements would be needed prior to expand this tool to additional areas; stresses that eu joint procurement should be used only in exceptional circumstances and for extraordinary public cross-border health threats where access to medicines cannot be ensured as efficiently by other means;


### 63. strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at eu level; ### 63. points out that joint procurement procedures for cancer medicines could improve affordability and access to cancer treatments at eu level;


### 63. strongly advocates the extension of joint procurement procedures for cancer medicines to improve affordability and access to cancer treatments at eu level; ### 63. strongly advocates the extension of joint procurement procedures for cancer health technologies to improve affordability and access to cancer treatments in all member states;


### 64. calls for a review of data exclusivity in the authorisation process of medicines29 , i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials , so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the covid-19 crisis) or to overcome the rising cost of specific treatments; ### 64. acknowledges the progress and improvements made in the eu regulations addressing the disclosure of sensitive and confidential information in the framework of the authorisation of medicines29; notes that exclusive access to certain information provides the necessary legal certainty to operators to develop innovative treatments and medicines in the fight against cancer;


### 64. calls for a review of data exclusivity in the authorisation process of medicines29 , i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials , so that compulsory licensing can allow for the market entry of cancer treatments in the event of a health crisis (such as the covid-19 crisis) or to overcome the rising cost of specific treatments; ### 64. calls for a review of data exclusivity in the authorisation process of medicines29 , i.e. the period of time within which the marketing authorisation holder of a medicine enjoys exclusive access to the results of preclinical tests and clinical trials , so that compulsory licensing can allow for the market entry of cancer treatments in the event of a major health crisis (such as the ongoing covid-19 pandemic) or to overcome the rising cost of specific treatments;


### 65. calls on the commission to submit a proposal for the revision of directive 89/105/eec on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines , in particular cancer medicines , in member states; calls for pharmaceutical companies to provide information on financing with public resources , as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the european medicines agency (ema) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; ### 65. calls on the commission to launch an in-depth assessment on the need to review directive 89/105/eec on the transparency of measures regulating the prices of medicinal products30; calls for pharmaceutical companies to provide information on financing with public resources , as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the european medicines agency (ema) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency;


### 65. calls on the commission to submit a proposal for the revision of directive 89/105/eec on the transparency of measures regulating the prices of medicinal products30 in order to ensure effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines , in particular cancer medicines , in member states; calls for pharmaceutical companies to provide information on financing with public resources , as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds; calls on the european medicines agency (ema) to increase the number of audits in order to assess pharmaceutical companies’ compliance with the requirements on transparency; ### 65. calls on the commission to submit a proposal for the revision of directive 89/105/eec on the transparency of measures regulating the prices of medicinal products30 in order to ensure , under the framework of member states internal regulations , effective controls and full transparency of the procedures used to determine the price and reimbursement of the cost of medicines , in particular cancer medicines , in member states; calls for pharmaceutical companies to provide information on financing with public resources , as well as on the tax benefits and subsidies they have received; requests that the calculation of drug costs should take into account the use of public funds;


### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; ### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various genetic alterations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment of patients;


### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; ### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients , in full respect of their data privacy , including ensuring that patients are informed of , and give permission for , the use of their health data;


### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to personalised treatment for patients; ### 66. notes that huge advances in biology have revealed that cancer is an umbrella term for more than 200 diseases , and that precision or personalised medicine can be made available through the drug targeting of various mutations; considers that precision or personalised medicine , consisting of a treatment choice based on individual tumour biomarkers , is a promising way to improve cancer treatment; encourages member states , therefore , to promote the implementation of regional molecular genetics platforms and facilitate equal and rapid access to advanced diagnostics and personalised treatment for patients;


### 68. calls for a more sustainable environment for conducting research into the repurposing of medicines for cancer treatment and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations , starting with treatment for cancers with a poor prognosis and rare cancers; ### 68. calls for a more sustainable and extensible environment for conducting new studies and analysing existing research on the repurposing of medicines for cancer treatment , reappraising the functionality of established therapies , and for the creation of an additional project that uses high-performance computing to rapidly test existing molecules and new drug combinations , starting with treatment for cancers with a poor prognosis and rare cancers;


### 70. welcomes the commission’s intention to adopt a legislative proposal to establish a health emergency preparedness and response authority (hera) in order to anticipate , incentivise , co-develop and facilitate rapid , equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities , private companies and ngos , including patient associations , to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies , for instance , cellular therapy (car t cells) , adoptive immunotherapy through the use of tumour genome extracts (messenger rna) and nanotechnologies; ### 70. takes note of the commission’s intention to adopt a legislative proposal to establish a health emergency preparedness and response authority (hera) in order to anticipate , incentivise , co-develop and facilitate rapid , equal and sustainable access to cancer innovations for cancer patients; calls for a large consortium of public authorities , private companies and stakeholders , including patient associations , to work together to guarantee the accessibility and affordability of cancer treatment options requiring complex technologies , for instance , cellular therapy (car t cells) , adoptive immunotherapy through the use of tumour genome extracts (messenger rna) and nanotechnologies;


### iii.c . equal access to cancer care: towards a better response to the impact of health crises on cancer patients ### iii.c . equal access to comprehensive , multidisciplinary and quality cancer care: towards a better response to the impact of health crises on cancer patients


### 71. underlines that the covid-19 crisis has had , and is still having , a significant impact on cancer patients’ survival and quality of life at all stages of the disease , due to delays in screening , referral and surgical procedures , treatment postponement , shortages in the supply of medicines and other medical supplies , specialised workforce shortages and reduced communication with health professionals; ### 71. underlines that the covid-19 crisis has had , and is still having , a significant impact on cancer patients’ survival and quality of life at all stages of the disease , due to delays in prevention activities such as hpv vaccination , screening , referral and surgical procedures , treatment postponement , shortages in the supply of medicines and other medical supplies , specialised workforce shortages and reduced communication with health professionals; highlights evidence suggesting that clinicians across europe saw 1.5 million fewer cancer patients in the first year of the pandemic , an estimated 100million cancer screening tests were not performed in europe as a result of the pandemic , and consequently , 1 million citizens in the eu may presently be undiagnosed with cancer as a consequence of the covid-19 pandemic;


### 71. underlines that the covid-19 crisis has had , and is still having , a significant impact on cancer patients’ survival and quality of life at all stages of the disease , due to delays in screening , referral and surgical procedures , treatment postponement , shortages in the supply of medicines and other medical supplies , specialised workforce shortages and reduced communication with health professionals; ### 71. underlines that the covid-19 crisis has had , and is still having , a significant impact on cancer patients’ survival and quality of life at all stages of the disease , due to delays in screening , referral and surgical procedures , treatment postponement , shortages in the supply of medicines and other medical supplies , specialised workforce shortages , reduced communication with health professionals and patients’ fear of infection;


### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals; ### 73. notes with concern that the covid-19 pandemic has exacerbated pre-existing health workforce shortages; acknowledges the urgency of ensuring a sufficient number of specialised health professionals in cancer care , doctors and nurses; reiterates that specific measures under the emergency strategy should be aimed at addressing workforce shortages through the recruitment of health professionals in both primary and specialized care;


### 74. advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; ### 74. advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home but without forgetting the value of face-to-face care and training provided by professional carers; calls for permanent access to medical consultations , nursing and psychosocial services to be guaranteed through the use of telemedicine and telecare or in health threat-free environments in hospitals;


### 74. advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; ### 74. advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; calls for the stimulation of the development of therapeutics that can support a transition to home care;


### 74. advocates the development of a digital health system to monitor symptoms and ensure cancer treatment and care at home; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine or in health threat-free environments in hospitals; ### 74. advocates the development of a digital health system to monitor symptoms and ensure continued cancer treatment in out-of-hospital care; calls for permanent access to medical consultations and psychosocial services to be guaranteed through the use of telemedicine technologies or safe hospitals in the event of a public health crisis or major event;


### 75. asks for enhanced communication between health professionals , patients and public authorities regarding the effectiveness and safety of health interventions , in particular cancer screening , diagnosis and treatment , and for increased awareness campaigns in times of crises; ### 75. asks for enhanced communication between health professionals , patients and public authorities regarding the effectiveness and safety of health interventions , in particular cancer screening , diagnosis and treatment , and for increased awareness campaigns for prevention and risk reduction in times of crises;


### iv. strong support to cancer patients , survivors and caregivers ### iv. survivors , their families and caregivers


### 77. stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the adoption of an anti-discrimination directive , as well as for the fair and equal implementation of directives on financial services , such as the consumer credit directive32 , without any discrimination against cancer patients and survivors; ### 77. stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the fair and equal implementation of directives on financial services , such as the consumer credit directive32 , without any discrimination against cancer patients and survivors;


### 77. stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the adoption of an anti-discrimination directive , as well as for the fair and equal implementation of directives on financial services , such as the consumer credit directive32 , without any discrimination against cancer patients and survivors; ### 77. stresses that cancer patients should not suffer a ‘double punishment’ in their daily lives; calls for the adoption of a set of recommendations on anti-discrimination , as well as for the fair and equal implementation of directives on financial services , such as the consumer credit directive32 , without any discrimination against cancer patients and survivors;


### 78. emphasises the importance of specific eu recommendations to improve the quality of life of patients , including via supportive care (pain relief , psychological services , adapted physical activity , nutritional support , social assistance , access to reproductive health and restoration of aesthetic integrity); asks member states for recognition of sequelae (physical or mental disabilities) , as well as social discrimination; ### 78. emphasises the importance of specific eu recommendations to improve the essential issues in the treatment of all cancer patients and their families , including via supportive integral care , from a bio-psycho-social perspective (pain relief , psychological services , adapted physical activity , nutritional support , social assistance and restoration of aesthetic integrity) integrated into cancer care from diagnosis and throughout the entire disease ; asks member states for recognition of sequelae (physical or mental disabilities) , as well as social discrimination;


### 78. emphasises the importance of specific eu recommendations to improve the quality of life of patients , including via supportive care (pain relief , psychological services , adapted physical activity , nutritional support , social assistance , access to reproductive health and restoration of aesthetic integrity); asks member states for recognition of sequelae (physical or mental disabilities) , as well as social discrimination; ### 78. emphasises the importance of specific eu recommendations to improve the quality of life of patients , including via supportive care (pain relief , psychological services , adapted physical activity , nutritional support , social assistance , access to reproductive health and restoration of aesthetic integrity); asks member states to do more in recognising sequelae (physical or mental disabilities) , as well as confronting social stigma and discrimination , which can limit opportunities for employment and social interaction;


### 79. encourages member states to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace; ### 79. encourages member states to take into account the frequent exhaustion of the families and relatives of cancer patients and to provide them with psychological assistance and rest periods in the workplace , as well as support during mourning; encourages also the development of integrated support schemes for cancer patients and their families , taking into account health , community and social services;


### 80. recalls that patient empowerment is crucial for the european cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education of caregivers and patients and their empowerment in the care programmes; ### 80. recalls that patient proactivity is crucial for the european cancer strategy and that patient-centeredness and participatory decision-making must be at the heart of treatment and care development processes; encourages the therapeutic education and self-care training of caregivers and patients and their engagement in the care programmes for the promotion of active and expert patients , using tools such as peer-to-peer learning;


### 81. acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the commission and the member states to take into account their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding; ### 81. acknowledges the positive role of patients’ associations in relation to patient advocacy and accompaniment; calls on the commission and the member states to take into account their formal participation , as well as their requests and recommendations when formulating cancer-related policies and legislation and to provide them with public support in order to guarantee their independence from private funding;


### 83. considers that the european agency for health and safety at work should be mandated to play a stronger role in promoting good practices in member states with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study , announced in europe’s beating cancer plan , on the return to work of cancer survivors , which will map national employment and social protection policies and identify obstacles and the remaining challenges; ### 83. considers that the european agency for health and safety at work should be mandated to play a stronger role in promoting good practices in member states with respect to the integration of cancer patients and survivors into the workplace and their protection from discrimination; looks forward to the new study , announced in europe’s beating cancer plan , on the return to work of cancer survivors , which will map national employment and social protection policies and identify obstacles and the remaining challenges , as well as the direct economic impact which cancer causes on patients and their families , taking into account their specific social and economic situation;


### — having regard to the un sustainable development goals (sdgs) , in particular sdg 3 on good health and well-being , ### deleted


### a. whereas europe’s beating cancer plan should effectively respond to the call for progress by the families and doctors of the 1.3 million people who die from cancer each year in europe , including 6 000 children , the crucial needs of patients who are currently in need of efficient and innovative treatments , the rightful expectations of more than 12 million cancer survivors facing the difficult return back to a ‘normal life’ , the clear will of future generations to be protected against health threats , and the concern of governments facing a growing economic burden from cancer and its related treatments; ### a. whereas europe’s beating cancer plan should effectively respond to the call for progress by the families and doctors and other health care professionals of the 1.3 million people who die from cancer each year in europe , including 6 000 children , the crucial needs of patients who are currently in need of efficient and innovative treatments , the rightful expectations of more than 12 million cancer survivors facing the difficult return back to a ‘normal life’ , the clear will of future generations to be protected against health threats , and the concern of governments facing a growing economic burden from cancer and its related treatments;


### b. whereas europe represents less than 10 % of the world’s population , but accounts for a quarter of all cancer cases , and whereas cancer is the second leading cause of death in europe after cardiovascular diseases; whereas although there has been a slight decrease in mortality rates thanks to screening campaigns and therapeutic innovation , the number of cases diagnosed is nevertheless increasing , notably due to longer life expectancies , which results in ageing populations; whereas almost three quarters of all cancer diagnoses in the eu occur in people aged 60 or above; ### b. whereas europe represents less than 10 % of the world’s population , but accounts for a quarter of all cancer cases , and whereas cancer is the second leading cause of death in europe after cardiovascular diseases; whereas , according to current projections , the number of diagnosed cases within the eu is expected to increase a further 25% by 2035; whereas although there has been a slight decrease in mortality rates thanks to screening campaigns and therapeutic innovation , the number of cases diagnosed is nevertheless increasing , notably due to longer life expectancies , which results in ageing populations; whereas almost three quarters of all cancer diagnoses in the eu occur in people aged 60 or above;


### b. whereas europe represents less than 10 % of the world’s population , but accounts for a quarter of all cancer cases , and whereas cancer is the second leading cause of death in europe after cardiovascular diseases; whereas although there has been a slight decrease in mortality rates thanks to screening campaigns and therapeutic innovation , the number of cases diagnosed is nevertheless increasing , notably due to longer life expectancies , which results in ageing populations; whereas almost three quarters of all cancer diagnoses in the eu occur in people aged 60 or above; ### b. whereas europe represents less than 10 % of the world’s population , but accounts for a quarter of all cancer cases , and whereas cancer is the second leading cause of death in europe after cardiovascular diseases; whereas although there has been a slight decrease in mortality rates thanks to screening campaigns , improved diagnostics and therapeutic innovation , the number of cases diagnosed is nevertheless increasing , notably due to longer life expectancies , which results in ageing populations; whereas almost three quarters of all cancer diagnoses in the eu occur in people aged 60 or above;


### c. whereas cancer illustrates social injustice in healthcare , as differences in cancer survival rates across the eu member states exceed 25 %; whereas eu citizens are unequal in terms of prevention , unequally protected against risk factors , unequally educated in terms of healthy behaviours and unequally equipped against misinformation; whereas eu citizens are unequal in terms of timely access to quality care from member state to member state and from region to region in any given country; whereas after recovery or when in remission , eu citizens are unequal in their ability to return to work , to be financially independent and to return to a harmonious familial , social and emotional life; ### c. whereas cancer highlights the serious discrepancies in healthcare , as differences in cancer survival rates across the eu member states exceed 25 %; whereas eu citizens are unequal in terms of prevention , unequally protected against risk factors , unequally educated in terms of healthy behaviours and unequally equipped against misinformation; whereas eu citizens are unequal in terms of timely access to quality care from member state to member state and from region to region in any given country; whereas after recovery or when in remission , eu citizens are unequal in their ability to return to work , to be financially independent and to return to a harmonious familial , social and emotional life;


### c. whereas cancer illustrates social injustice in healthcare , as differences in cancer survival rates across the eu member states exceed 25 %; whereas eu citizens are unequal in terms of prevention , unequally protected against risk factors , unequally educated in terms of healthy behaviours and unequally equipped against misinformation; whereas eu citizens are unequal in terms of timely access to quality care from member state to member state and from region to region in any given country; whereas after recovery or when in remission , eu citizens are unequal in their ability to return to work , to be financially independent and to return to a harmonious familial , social and emotional life; ### c. whereas cancer illustrates gaps in healthcare , as differences in cancer survival rates across the eu member states exceed 25 %; whereas eu citizens are unequal in terms of prevention , unequally protected against risk factors , unequally educated in terms of healthy behaviours and unequally equipped against misinformation; whereas eu citizens are unequal in terms of timely access to quality care from member state to member state and from region to region in some eu member states; whereas after recovery or when in remission , eu citizens are unequal in their ability to return to work , to be financially independent and to return to a harmonious familial , social and emotional life;


### e. whereas the goal of europe’s beating cancer plan should not only be to fight against a crucial public health issue and to help patients live longer and better lives , but should also be to initiate a reduction in health inequalities and inequities and lower the social and economic burden of the disease; whereas the commission should promote a patient-centred and citizens’ rights-based approach by integrating considerations of justice , sustainability , equity , solidarity , innovation and collaboration at the very core of europe’s beating cancer plan; ### e. whereas europe’s beating cancer plan should aim at tackling this crucial public health issue helping patients live longer and better lives , but should also encourage better access to health services; whereas the commission should promote a patient-centred and citizens’ rights-based approach by integrating considerations of justice , sustainability , equity , solidarity , innovation and collaboration at the very core of europe’s beating cancer plan;


### e. whereas the goal of europe’s beating cancer plan should not only be to fight against a crucial public health issue and to help patients live longer and better lives , but should also be to initiate a reduction in health inequalities and inequities and lower the social and economic burden of the disease; whereas the commission should promote a patient-centred and citizens’ rights-based approach by integrating considerations of justice , sustainability , equity , solidarity , innovation and collaboration at the very core of europe’s beating cancer plan; ### e. whereas the goal of europe’s beating cancer plan should not only be to fight against a crucial public health issue and to help patients live longer and better lives , but should also be to assist member states in improving cancer care and lowering the social and economic burden of the disease; whereas the commission should work together with member states to promote a patient-centred approach by integrating considerations of innovation and collaboration at the very core of europe’s beating cancer plan;


### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions to promote health literacy under the plan should focus on empowering patients and citizens; whereas all efforts to increase health literacy should take into account people with learning disabilities , as well as ensure that the necessary information is available in common non-eu languages in order to reach migrants and new arrivals; ### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions under the plan should focus on enabling patients and citizens to promote health literacy; whereas all efforts to increase health literacy should take into account people with learning disabilities , as well as ensure that the necessary information is available in common non-eu languages in order to reach regularised migrants and new legal arrivals;


### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions to promote health literacy under the plan should focus on empowering patients and citizens; whereas all efforts to increase health literacy should take into account people with learning disabilities , as well as ensure that the necessary information is available in common non-eu languages in order to reach migrants and new arrivals; ### f. whereas health literacy includes the acquisition of knowledge and skills , awareness of rights and the confidence to take action to improve personal and community health; whereas actions to promote health literacy under the plan should focus on empowering patients and citizens; whereas all efforts to increase health literacy should take into account people with learning disabilities;


### g. whereas the plan should be implemented in close association with the recommendations and actions of the international agency for research on cancer (iarc) , the un sdgs for global health , and the recommendations and guidelines of the world health organization (who) , and should acknowledge as a priority the eu’s solidarity and partnership with low- and middle-income countries; ### g. whereas the plan should be implemented in close association with the recommendations and actions of the international agency for research on cancer (iarc) , and the recommendations and guidelines of the world health organization (who) relating to cancer , and should acknowledge as a priority the eu’s solidarity and partnership with low- and middle-income countries in the fight against cancer;


### g. whereas the plan should be implemented in close association with the recommendations and actions of the international agency for research on cancer (iarc) , the un sdgs for global health , and the recommendations and guidelines of the world health organization (who) , and should acknowledge as a priority the eu’s solidarity and partnership with low- and middle-income countries; ### g. whereas the plan should be implemented in close association with the recommendations and actions of the international agency for research on cancer (iarc) , the un sdgs for global health , and the recommendations and guidelines of the world health organization (who) , and should acknowledge the eu’s solidarity and partnership with low- and middle-income countries;


### h. whereas addressing cancer could be used as a model for other non-communicable diseases , and whereas patients with other chronic diseases should therefore also benefit from the achievements of europe’s beating cancer plan; ### h. whereas addressing cancer in a comprehensive strategy presented by the commission , via the setting up of a dedicated committee in the parliament and through a series of hearings with experts , academia , healthcare professionals and patient organisations could be used as a model for other non-communicable diseases , and whereas patients with other chronic diseases should therefore also benefit from the achievements of europe’s beating cancer plan;


### i. whereas a common policy driven at european level is absolutely essential for progress in the area of cancer; whereas the primary responsibility for health protection and healthcare systems lies with the member states; ### i. whereas collaboration between member states encouraged by the eu is absolutely essential for progress in the area of cancer; whereas the primary responsibility for health protection and healthcare systems lies with the member states;


### i. whereas a common policy driven at european level is absolutely essential for progress in the area of cancer; whereas the primary responsibility for health protection and healthcare systems lies with the member states; ### i. whereas a common policy driven by cooperation at european level is absolutely essential for progress in the area of cancer; whereas the primary responsibility for health protection and healthcare systems lies with the member states;


### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research; ### j. whereas a comprehensive , multidisciplinary and coordinated approach to addressing social , individual , environmental and commercial health determinants is needed at regional , national and european level in order to support actions targeting all aspects of cancer (prevention , detection , treatment , palliative care and reintegration) through the effective mobilisation of key tools such as research and knowledge sharing; whereas new technologies and artificial intelligence have high potential for improvements in the field of cancer research , while adhering to the high eu standards for personal data protection; whereas with all ai-based technologies , human oversight must at all times be guaranteed;


### k. whereas the ‘health in all policies’ and ‘one health’ approaches should be promoted further , and efforts to fight cancer should be integrated into all eu policies; ### k. whereas efforts to fight cancer should be a priority in eu policies;


### k. whereas the ‘health in all policies’ and ‘one health’ approaches should be promoted further , and efforts to fight cancer should be integrated into all eu policies; ### k. whereas the ‘health in all policies’ and ‘one health’ approaches could be promoted further in areas where the commission and member states find gaps , and efforts to fight cancer should be integrated , where appropriate , into all relevant eu policies;


### m. whereas europe’s beating cancer plan could therefore represent the first step towards a real european health union; ### deleted


### m. whereas europe’s beating cancer plan could therefore represent the first step towards a real european health union; ### m. whereas europe’s beating cancer plan could therefore represent the first step towards a collaborative approach among member states in the fight against major diseases;


### 1. strongly believes that preventive actions against cancer should be implemented in all european policies and funding programmes; ### 1. strongly believes in preventive actions against cancer;


### 1. strongly believes that preventive actions against cancer should be implemented in all european policies and funding programmes; ### 1. strongly believes that preventive actions against cancer should be implemented in all relevant european policies and funding programmes;


### 2. calls on the commission and member states to design and implement effective prevention measures at national and eu level , based on best practices , independent expertise and guidance; ### 2. calls on the commission and member states to implement the european code against cancer (ecac) to reduce cancer risk based on the latest scientific evidence on cancer prevention , lessons learnt , best practices , independent expertise and guidance and moreover , update ecac on a regular basis using a planning cycle that supports a sustained process of monitoring and evaluation;


### 2. calls on the commission and member states to design and implement effective prevention measures at national and eu level , based on best practices , independent expertise and guidance; ### 2. calls on the commission and member states to design and implement effective prevention and risk reduction measures at national and eu level , based on best practices , scientific data and independent expertise and guidance;


### 3. acknowledges that more than 40 % of all cancers are preventable through coordinated actions on social , individual , environmental and commercial health determinants; ### 3. acknowledges that more than 40 % of all cancers are preventable through coordinated actions on social , individual , environmental and commercial health determinants , which are common to other major chronic diseases , and actions to address those can therefore bring positive results on disease prevention in general while also improving the health of the population;


### 4. supports the aim of the horizon europe cancer mission to avert more than 3 million additional premature deaths over the 2021-2030 period , by accelerating progress in cancer prevention and control programmes and creating more equal access to these programmes; ### 4. supports the aim of horizon europe's mission on cancer to avert more than 3 million additional premature deaths over the 2021-2030 period , by accelerating progress in cancer prevention , organised screenings , and early diagnosis programmes and creating more equal access;


### 4. supports the aim of the horizon europe cancer mission to avert more than 3 million additional premature deaths over the 2021-2030 period , by accelerating progress in cancer prevention and control programmes and creating more equal access to these programmes; ### 4. supports the aim of the horizon europe cancer mission to avert more than 3 million additional premature deaths over the 2021-2030 period , by accelerating progress in cancer prevention and control programmes and creating more equal opportunities for access to these programmes;


### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to pay special attention to vulnerable and marginalised populations in order to ensure their access to cancer prevention services; ### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to pay special attention to vulnerable and marginalised populations , particularly the elderly and those living in remote and isolated regions , in order to ensure their access to cancer prevention services;


### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to pay special attention to vulnerable and marginalised populations in order to ensure their access to cancer prevention services; ### 5. deplores the significant health inequalities in the eu as regards cancer prevention; insists on the need to assist vulnerable and marginalised populations in order to ensure their access to cancer prevention services;


### an increase in minimum excise duties for all tobacco products , which could result in a reduction in tobacco use , notably among young people; ### deleted


### a ban on flavourings in all tobacco products to reduce the appeal of these products to non-smokers and young people; ### deleted


### an authorisation for member states to introduce a ban on plastic cigarette filters on health and environmental grounds; ### deleted


### an authorisation for member states to introduce a ban on plastic cigarette filters on health and environmental grounds; ### an authorisation for member states to introduce safeguards on cellulose acetate cigarette filters , particularly in view of recent studies demonstrating a link between the use of tobacco products with filter ventilation and adenocarcinoma1a.


### the continuation of evaluations of the health risks related to electronic cigarettes and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security; ### the continuation of evaluations of the reduced health risks related to electronic cigarettes and their role on reducing smoking prevalence , taking into account international best practices and most recent scientific evidence , including data on consumer preferences such as the 'special eurobarometer 506' survey on the attitude of europeans towards tobacco and electronic cigarettes , and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security;


### the continuation of evaluations of the health risks related to electronic cigarettes and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security; ### the continuation of evaluations of the health risks related to all novel tobacco and emerging products and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security;


### the continuation of evaluations of the health risks related to electronic cigarettes and the establishment of a list of substances contained and emitted by these products at european level , based on the model published by the french agency for health security; ### the continuation of evaluations of the health risks related to electronic cigarettes and the establishment of a list of substances contained and emitted by these products at european level;


### 10. supports the commission’s proposal to update the council recommendation of 30 november 2009 on smoke-free environments12 to extend its coverage to emerging products , such as e-cigarettes and heated tobacco products , and to extend smoke-free environments , including outdoor spaces; ### 10. supports the commission’s proposal to update the council recommendation of 30 november 2009 on smoke-free environments12; calls for the launch of an in-depth study on the effects of emerging products , such as e-cigarettes and heated tobacco products and for assessing whether the council recommendation of 30 november 2009 on smoke-free environments should be extended to cover such products , and to extend smoke-free environments , including outdoor spaces;


### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to alcohol consumption; ### 11. recalls that acetaldehyde from ethanol metabolism is classified as carcinogenic to humans by the iarc , and that in europe an estimated 4.3 % of all cancer cases are attributable to alcohol consumption;


### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to alcohol consumption; ### 11. recalls that acetaldehyde from ethanol metabolism is classified as carcinogenic to humans by the iarc , and that in europe an estimated 10% of all cancer cases in men and 3% of all cancer cases in women are attributable to excessive alcohol consumption;


### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to alcohol consumption; ### 11. recalls that ethanol and acetaldehyde in alcoholic beverages are classified as carcinogenic to humans by the iarc , and that in europe an estimated 10 % of all cancer cases in men and 3 % of all cancer cases in women are attributable to an excessive overconsumption of alcohol , as defined by the who;


### 85. considers that insurers and banks should not take into account the medical history of people who have been affected by cancer; calls for national legislation to ensure that cancer survivors are not discriminated against compared to other consumers; notes the commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports , in parallel , the promotion of advances made in france , belgium , luxembourg and the netherlands , where cancer survivors enjoy the ‘right to be forgotten’; requests that by 2025 , at the latest , all member states should guarantee the right to be forgotten to all european patients ten years after the end of their treatment , and five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the right to be forgotten under the relevant provisions on consumer protection policy of the treaty on the functioning of the european union , in order to remedy the fragmented national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors; ### 85. considers that insurers and banks should be supported by member states so that people who have been affected by cancer are treated fairly and are not punished twice for their disease ; notes the commission’s intention to engage with businesses to develop a code of conduct to ensure that developments in cancer treatments and their improved effectiveness are reflected in the business practices of financial service providers; supports , in parallel , the promotion of advances made in france , belgium , luxembourg and the netherlands , where cancer survivors enjoy the ‘right to be forgotten’; requests that by 2025 , at the latest , all member states should guarantee the right to be forgotten to all european patients ten years after the end of their treatment , and five years after the end of treatment for patients whose diagnosis was made before the age of 18; calls for the introduction of common standards for the right to be forgotten to inspire national practices in the area of creditworthiness assessment and ensure equal access to credit for cancer survivors;


### 86. calls on the commission to support the european code of cancer care launched by the european cancer organisation (eco) , which is an empowering and informative tool to ensure that the best available care is provided to european citizens and patients; ### 86. calls on the commission to support the european code of cancer care launched by the european cancer organisation (eco) , which is an empowering planning and support tool to ensure that the best available care is provided to european patients as well as informing citizens and their family members about healthy lifestyle choices they can take to reduce cancer risk;


### 87. sees an urgent need for a european charter of the rights of cancer patients; calls for this charter to define the rights of cancer patients at every stage of their care pathway , i.e. access to prevention , initial diagnosis and throughout their treatment , and for it to apply equally to all eu citizens , regardless of the country or region in which they live; ### 87. sees an urgent need for a european code of best practices against cancer ; calls for this code to take into account every stage of the cancer care pathway , i.e. access to prevention , initial diagnosis and throughout their treatment , and for it to apply equally to all eu citizens , regardless of the country or region in which they live;


### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; ### 92. calls for the introduction of significant changes in the regulations on paediatric33 and orphan34 medicinal products and other effective financing provisions in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs and innovative clinical trials for paediatric cancer , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends a substantial increase in the available new paediatric cancer drugs by 2027;


### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027; ### 92. calls for an ambitious revision of the regulations on paediatric33 and orphan34 medicinal products in order to ensure access to innovative cancer drugs , identify the most important drugs to meet the needs of children with poor prognostic cancers , reduce delays so that children can have faster access to paediatric drugs , stimulate competition by adapting a regulatory framework and stimulating investments in off-patent orphan and paediatric medicines , and address limited access to certain essential medicines due to drug shortages and the high price of innovative medicines; recommends an increase of 20 % in the available new paediatric cancer drugs by 2027;


### 97. stresses that europe’s beating cancer plan should be implemented in close cooperation with the cancer mission under horizon europe and its objectives of promoting eu investment in cancer research and innovation; ### 97. stresses that europe’s beating cancer plan should be implemented in close cooperation with the mission on cancer under horizon europe and its objectives of promoting eu investment in cancer research and innovation;


### 99. reiterates its call for sustainable and adequate funding for competitive european research on cancer; calls for at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations; ### 99. reiterates its call for adequate funding for competitive european research on cancer; calls for at least a 20 % increase in the mobilisation of public and private research on therapeutic and diagnostic cancer innovations;


### 100. stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’ , that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation , especially on social media; ### 100. stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’ , that is from the laboratory to applied studies in patients; urges the establishment of measures to foster scientific information about cancer research , especially on social media;


### 100. stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’ , that is from the laboratory to applied studies in patients; urges the establishment of measures to limit misinformation , especially on social media; ### 100. stresses the need for independent and multidisciplinary research on cancer ‘from bench to bedside’ , that is from the laboratory to applied studies in patients; urges the establishment of measures to limit the health risks posed by disinformation and misinformation , especially on social media;


### 104. supports the creation of new digital resources and platforms , such as the european cancer imaging initiative , and the strengthening of the european cancer information system , which will enable competent authorities to make good use of artificial intelligence applied to big data in the years to come; ### 104. supports the creation of new digital resources and platforms , such as the european cancer imaging initiative , and the strengthening of the european cancer information system , which will enable competent authorities to make good use of artificial intelligence applied to big data in the years to come; notes that , by using technologies such as natural language processing , this methodology would make it possible to design and develop algorithms aimed at identifying different events that may occur throughout the evolution of cancer patients; notes that , through these predictive models , it would be possible to establish for each patient the probability of recurrence or death due to the disease or the probability of presenting serious toxicity secondary to treatment , so that the identification of such events would allow for early action to be taken;


### 105. welcomes the launch of the ‘cancer diagnostic and treatment for all’ flagship initiative under europe’s beating cancer plan , whose aim is to improve access to innovative cancer diagnosis and treatment and promote the use of the ‘next generation sequencing’ technology for quick and efficient genetic profiles of tumour cells , allowing researchers and clinicians to share cancer profiles and apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles; ### 105. welcomes the launch of the ‘cancer diagnostic and treatment for all’ flagship initiative under europe’s beating cancer plan , whose aim is to improve access to innovative cancer diagnosis and treatment , as well as comprehensive professional care for patients and their families , and promote the use of the ‘next generation sequencing’ technology for quick and efficient genetic profiles of tumour cells , allowing researchers and clinicians to share cancer profiles and apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles;


### 112. advocates more transparency in the process of research into and the development of cancer treatments , including the establishment of a portal to allow patients access to information on the available clinical trials in europe; ### 112. advocates more transparency in the research and development of cancer treatments , including the establishment of a portal to allow patients access to information on the available clinical trials in europe;


### 119. welcomes the launch of a knowledge centre on cancer in 2021 , announced in europe’s beating cancer plan , in order to contribute to the exchanges and coordination of scientific and technical initiatives related to cancer at eu level; believes that this knowledge centre should be based on data screening , ern reports and cancer registries , and be part of a european cancer institute; ### 119. welcomes the launch of a knowledge centre on cancer in 2021 , announced in europe’s beating cancer plan , in order to contribute to the exchanges and coordination of scientific and technical initiatives related to cancer at eu level; believes that this knowledge centre should be based on data screening , ern reports and cancer registries , and be part of an association of european cancer institutes;


### 120. recommends the creation of at least one cancer registry in each eu region , including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence , prevalence and survival; asks member states to ensure the comparability of data sources and the interoperability of regional and national cancer registries; ### 120. recommends the creation of at least one cancer registry in each eu region , including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence , prevalence and survival; asks member states to ensure the comparability of data sources and the interoperability of regional and national cancer registries; stresses the essential need to collect data collaboratively across all member states;


### 120. recommends the creation of at least one cancer registry in each eu region , including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence , prevalence and survival; asks member states to ensure the comparability of data sources and the interoperability of regional and national cancer registries; ### 120. recommends the creation of at least one cancer registry in each eu region , as well as within each member state , including remote and outermost regions; supports the strengthening of the capacity of national cancer registries to collect data (including lifestyle and socio-economic information) to better identify the causes of inequalities in cancer incidence , prevalence and survival; asks member states to ensure the comparability of data sources and the interoperability of regional and national cancer registries;


### 122. supports the commission’s intention to enable cancer patients to securely access and share electronic health records across borders; considers that the commission could lay the foundation for the european health data space , in association with digital health europe , by collecting and analysing anonymised medical data (from cancer registries , hospitals , academic clinical trials and cohorts) and biological data (from blood and tumour samples) in a european cancer cloud hosted by a european cancer institute; encourages the use of health data for non-commercial purposes (‘data altruism’); welcomes the planned creation of a virtual european cancer patient digital centre under horizon europe’s mission on cancer in order to support a standardised approach to the participation of willing patients in the deposit and exchange of their health data; recommends the inclusion of patients in any actions related to the storage and use of health data for policy-making and research purposes; welcomes the planned expansion of the european cancer information system before 2022; ### 122. supports the commission’s intention to enable cancer patients to securely access and share electronic health records across borders; considers that the commission could lay the foundation for the european health data space , in association with digital health europe , by collecting , analysing and exchanging anonymised medical data (from cancer registries , hospitals , academic clinical trials and cohorts) and biological data (from blood and tumour samples) in a european cancer cloud hosted by an association of european cancer institutes; encourages the use of health data for non-commercial purposes (‘data altruism’); welcomes the planned creation of a virtual european cancer patient digital centre under horizon europe’s mission on cancer in order to support a standardised approach to the participation of willing patients in the deposit and exchange of their health data; recommends the inclusion of patients in any actions related to the storage and use of health data for policy-making and research purposes; welcomes the planned expansion of the european cancer information system before 2022;


### 123. calls for improved standards in the education and training of health professionals; encourages common and multidisciplinary training programmes for health professionals in close collaboration with european learned societies; welcomes the launch of an inter-specialty cancer training programme , which will involve cooperation between member states via a european cancer institute; ### 123. calls for improved standards in the education and training of health professionals; encourages common and multidisciplinary training programmes for health professionals in close collaboration with european learned societies; welcomes the launch of an inter-specialty cancer training programme , which will involve cooperation between member states via an association of european cancer institutes;


### iii. creation of a european cancer institute ### iii. creation of an association of european cancer institutes


### 124. calls for the creation of a virtual european cancer institute , involving all stakeholders (representatives of each nccp , patients’ and caregivers’ associations , learned societies etc.) , in charge of the following missions: ### 124. calls for the creation of an association of european cancer institutes , involving all stakeholders (representatives of each nccp , patients’ and caregivers’ associations , learned societies etc.) , in charge of the following missions:


### 124. calls for the creation of a virtual european cancer institute , involving all stakeholders (representatives of each nccp , patients’ and caregivers’ associations , learned societies etc.) , in charge of the following missions: ### 124. calls for the creation of a virtual european cancer institute , involving all stakeholders (representatives of each nccp , patients’ and caregivers’ associations , learned societies , as well as economic operators etc.) , in charge of the following missions:


### 126. calls on the member states to ensure that enough funds are allocated for the appropriate implementation of the plan and of their respective nccps; considers that no more than 30 % of europe’s beating cancer plan should be allocated to the implementation of the nccps; ### 126. calls on the member states to ensure that enough funds are allocated for the appropriate implementation of the plan and of their respective nccps; notes that in view of the different administrative and political systems in member states , the europe’s beating cancer plan must take national specificities into account when allocating funding to the implementation of the nccps;


### b. whereas albania is a reliable foreign policy partner , including through its engagement in the un security council; ### b. whereas albania is a reliable foreign policy partner , including through its active engagement in the un security council and nato;


### 1. welcomes albania’s steadfast commitment to eu integration , reflecting the consensus among political parties and overwhelming support among citizens; commends its solidarity and consistent , full alignment with the eu’s foreign and security policy , including its clear-cut response to the russian war of aggression against ukraine; ### 1. welcomes albania’s steadfast commitment to eu integration , reflecting the consensus among political parties and overwhelming support among citizens; commends its solidarity and consistent , full alignment with the eu’s foreign and security policy , including its clear-cut response to the russian war of aggression against ukraine and by joining eu restrictive measures on russia;


### 2. encourages its policymakers to accelerate the reforms that enabled the first long overdue intergovernmental conference and a successful start to the screening process , and to demonstrate steady progress in guaranteeing democracy , the rule of law and fundamental rights; urges decision-makers to work jointly towards meeting the membership criteria by 2030; stresses the need to strengthen the transparency , accountability and inclusiveness of the accession process , including its parliamentary dimension; ### 2. encourages its policymakers to accelerate the reforms that enabled the first long overdue intergovernmental conference and a successful start to the screening process , and to demonstrate steady and visible progress in guaranteeing democracy , the rule of law and fundamental rights; urges decision-makers to work jointly towards meeting the membership criteria by 2030; stresses the need to strengthen the transparency , accountability and inclusiveness of the accession process , including its parliamentary dimension;